- Saunders‐Pullman, Rachel;
- Alcalay, Roy N;
- Mirelman, Anat;
- Wang, Cuiling;
- San Luciano, Marta;
- Ortega, Roberto A;
- Glickman, Amanda;
- Raymond, Deborah;
- Mejia‐Santana, Helen;
- Doan, Nancy;
- Johannes, Brooke;
- Yasinovsky, Kira;
- Ozelius, Laurie;
- Clark, Lorraine;
- Orr‐Utreger, Avi;
- Marder, Karen;
- Giladi, Nir;
- Bressman, Susan B;
- Consortium, the AJ LRRK2
Background
Rapid eye movement sleep behavior disorder occurs with idiopathic Parkinson's disease (PD) and often precedes PD. Its frequency in LRRK2-PD and utility as a preclinical marker has not been established.Methods
One hundred forty-four idiopathic PD, 142 LRRK2 G2019S mutation PD, 117 non-manifesting carriers, 93 related noncarriers, and 40 healthy controls completed the Rapid eye movement sleep Behavior Disorder Screening Questionnaire.Results
Cut scores were met by 30.6% idiopathic PD, 19.7% LRRK2-PD, 6% nonmanifesting carriers, 20.4% related noncarriers, and 15% controls. The likelihood of abnormal scores was decreased in LRRK2-PD versus idiopathic PD (odds ratio = 0.55, P = 0.03), nonmanifesting carriers versus related noncarriers (OR = 0.25, P < 0.01), and PD of less than 3 years' duration, 1 of 19 LRRK2-PD versus 14 of 41 idiopathic PD (P < 0.05).Conclusions
A lower frequency of abnormal questionnaire scores is seen in LRRK2-PD, especially in early LRRK2-PD, and in nonmanifesting carriers. Therefore, the Rapid eye movement sleep Behavior Disorder Questionnaire is unlikely to serve as a preclinical marker for phenoconversion to PD.